Education
About Us
Working with TipRanks
Follow Us
Vera Therapeutics, Inc. (VERA)
NASDAQ:VERA
Total Valuation
Vera Therapeutics has a market cap or net worth of $2.79B. The enterprise value is $2.51B.
Market Cap$2.79B
Enterprise Value$2.51B
Share Statistics
Vera Therapeutics has 71,355,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,355,670
Owned by Insiders13.27%
Owned by Institutions1.48%
Financial Efficiency
Vera Therapeutics’s return on equity (ROE) is -0.50 and return on invested capital (ROIC) is -46.27%.
Return on Equity (ROE)-0.50
Return on Assets (ROA)-0.41
Return on Invested Capital (ROIC)-46.27%
Return on Capital Employed (ROCE)-0.46
Revenue Per Employee0.00
Profits Per Employee-1.97M
Employee Count152
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Vera Therapeutics is ―. Vera Therapeutics’s PEG ratio is -0.16.
PE Ratio―
PS Ratio0.00
PB Ratio5.38
Price to Fair Value5.38
Price to FCF-13.46
Price to Operating Cash Flow-10.41
PEG Ratio-0.16
Income Statement
In the last 12 months, Vera Therapeutics had revenue of 0.00 and earned -299.62M in profits. Earnings per share was -4.66.
Revenue0.00
Gross Profit-468.00K
Operating Income-315.47M
Pretax Income-299.62M
Net Income-299.62M
EBITDA-291.62M
Earnings Per Share (EPS)-4.66
Cash Flow
In the last 12 months, operating cash flow was -241.10M and capital expenditures -630.00K, giving a free cash flow of -241.73M billion.
Operating Cash Flow-241.10M
Free Cash Flow-241.73M
Free Cash Flow per Share-3.39
Dividends & Yields
Vera Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.34
52-Week Price Change40.54%
50-Day Moving Average45.30
200-Day Moving Average31.70
Relative Strength Index (RSI)36.31
Average Volume (3m)993.25K
Important Dates
Vera Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Vera Therapeutics as a current ratio of 13.64, with Debt / Equity ratio of 12.79%
Current Ratio13.64
Quick Ratio13.64
Debt to Market Cap0.02
Net Debt to EBITDA0.95
Interest Coverage Ratio-41.89
Taxes
In the past 12 months, Vera Therapeutics has paid -1.00K in taxes.
Income Tax-1.00K
Effective Tax Rate<0.01
Enterprise Valuation
Vera Therapeutics EV to EBITDA ratio is -10.20, with an EV/FCF ratio of -12.31.
EV to Sales0.00
EV to EBITDA-10.20
EV to Free Cash Flow-12.31
EV to Operating Cash Flow-12.34
Balance Sheet
Vera Therapeutics has $714.59M in cash and marketable securities with $77.31M in debt, giving a net cash position of $637.28M billion.
Cash & Marketable Securities$714.59M
Total Debt$77.31M
Net Cash$637.28M
Net Cash Per Share$8.93
Tangible Book Value Per Share$9.41
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Vera Therapeutics is $77.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$77.25
Price Target Upside97.72% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast-53.44%